Cresset Asset Management LLC Decreases Stake in Natera, Inc. (NASDAQ:NTRA)

Cresset Asset Management LLC trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 43.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,867 shares of the medical research company's stock after selling 2,220 shares during the period. Cresset Asset Management LLC's holdings in Natera were worth $454,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. boosted its position in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares during the last quarter. Principal Securities Inc. boosted its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after buying an additional 332 shares during the last quarter. Finally, Global Retirement Partners LLC raised its stake in shares of Natera by 55.0% in the 4th quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company's stock worth $69,000 after buying an additional 154 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Price Performance

NTRA stock traded down $0.79 during midday trading on Wednesday, reaching $153.74. The company had a trading volume of 151,323 shares, compared to its average volume of 1,380,469. The stock has a 50 day moving average price of $149.13 and a 200-day moving average price of $157.15. The company has a market capitalization of $20.99 billion, a price-to-earnings ratio of -87.65 and a beta of 1.79. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the previous year, the firm earned ($0.56) EPS. Natera's revenue was up 36.5% on a year-over-year basis. Equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research analyst reports. Robert W. Baird lifted their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Barclays increased their price objective on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and issued a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Finally, Royal Bank of Canada started coverage on Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price for the company. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $182.12.

Insider Transactions at Natera

In other Natera news, Director Gail Boxer Marcus sold 4,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the sale, the director now directly owns 9,704 shares in the company, valued at approximately $1,433,183.76. This trade represents a 29.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now directly owns 203,354 shares of the company's stock, valued at $29,160,963.60. This represents a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 152,436 shares of company stock worth $22,019,079. Corporate insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.